Aura Biosciences' Engagement at Healthcare Conferences
Aura Biosciences, Inc. (NASDAQ: AURA), a pioneering clinical-stage biotechnology firm, is excited to announce its participation in an upcoming event that highlights its innovative developments in precision therapies. Leading this engagement will be Elisabet de los Pinos, PhD, the Chief Executive Officer, who will share insights during a fireside chat.
Details of the Upcoming Conference
The 8th Annual Evercore Healthcare Conference is set to take place soon, where Dr. de los Pinos will partake in discussions about the latest advancements in oncology. The session is scheduled for 10:50 a.m. ET, providing an opportunity for the audience to learn more about the company’s mission and groundbreaking technologies in cancer treatment.
Live Webcast Availability
For those who cannot attend in person, Aura Biosciences will offer a live webcast of the fireside chat, allowing a wider audience to engage with the conversation. This webcast will be accessible through the “Investors & Media” page on Aura’s official website, particularly in the “Events & Presentations” section.
Event Follow-Up and Replay
The company ensures that participants can revisit the insights shared during the conference, as a replay will be made available for 90 days post-event. This enables continuous learning and engagement for stakeholders interested in the latest developments in precision oncology.
About Aura Biosciences’ Vision
At the core of Aura Biosciences is a commitment to innovation and excellence in healthcare. The company is dedicated to developing precision therapies specifically for solid tumors with the aim of preserving organ function. Its lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and is also being evaluated for other indications, including bladder cancer.
The Mission Behind Innovation
Aura Biosciences’ primary mission is to transform the lives of patients suffering from various forms of cancer through innovative treatments. The company strives to be a leader in global oncology, continually researching and developing therapies that provide hope and positive outcomes for patients.
Connect with Aura Biosciences
The firm invites everyone interested in its journey and advancements to visit their official website for more detailed information about their pipeline and ongoing research. They are active on various social media platforms, allowing the community to stay updated on their latest milestones.
Investor and Media Relations
For inquiries related to investments or media coverage, Alex Dasalla, the Head of Investor Relations and Corporate Communications, is available to provide information. Interested parties can reach out directly for further details regarding Aura Biosciences' initiatives and corporate activities.
Frequently Asked Questions
What is the purpose of Aura Biosciences' participation in the conference?
Aura Biosciences is participating to share insights on their innovative therapies and advancements in the field of oncology.
How can I access the live webcast of the conference?
The live webcast will be available on the Aura Biosciences website under the “Investors & Media” section.
What is the significance of bel-sar (AU-011)?
Bel-sar (AU-011) is a lead therapeutic candidate aimed at treating early choroidal melanoma and other conditions, highlighting Aura's commitment to preserving organ function.
How long will the replay of the webcast be available?
The replay will be available for 90 days following the presentation date, allowing audiences to revisit the discussions.
Who can I contact for more information about Aura Biosciences?
Alex Dasalla serves as the contact for investor and media relations and can provide further information about the company and its initiatives.
